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Background: Pre-diabetes is a disturbing trend in the population, who are at risk of developing type-two diabetes.
The aim of this study was to determine the effects use of Aloe vera in different doses on glucose and lipid profile
in pre-diabetic subjects.
Methods: This study was a double blind randomized controlled trial (72 subjects) with pre-diabetes symptoms in 3
groups consumed capsules twice a day: Aloe vera 300 mg (AL300), 500 mg (AL500) and placebo (PL). Fasting blood
glucose (FBS), HbA1C and lipid profile were evaluated in baseline, 4 or 8 weeks. On-way ANOVA, Friedman, Wilcoxon,
Kruskal-Wallis , Mann–Whitney and Chi-square tests were used for within or between groups statistical analysis.
Results: FBS level in group AL300, showed significantly decreased in fourth week after the intervention, compared to
PL in the same time (p = 0.001). Also, HbA1C level in this group at the eighth week after the intervention (p = 0.042),
had a significant decrease. The levels of Total cholesterol and LDL-C, only in the group AL500 (p < 0.001 and p = 0.01),
was significantly reduced, along with HDL-C level improvement just after eight weeks (p = 0.004). Triglyceride level
showed a significant decrease (p < 0.045) just after four weeks use of AL500.
Conclusions: The Use of Aloe vera extract in pre-diabetic patients, could revert impaired blood glucose within four
weeks, but after eight weeks could alleviate their abnormal lipid profile.
Keywords: Aloe vera, Pre-diabetis, Fast blood glucose, Lipid profile, Herbal medicineIntroduction
Pre-diabetes and metabolic syndrome, which follows it,
are parts of interrelated common clinical disorders that
are accompanied by symptoms of obesity, insulin resist-
ance, glucose intolerance, lipid abnormalities, impaired
fasting glucose, and Impaired glucose tolerance (IGT)
[1]. According to statistics, 470 million people will be
suffering pre-diabetes by 2030 [2]. Some studies have re-
ported that approximately 5-10% of pre-diabetic popula-
tion would suffer from diabetes and problems associated
with it in around a year such as heart problems, imbal-
ance in glucose and lipid metabolism, and vascular
disorders. Timely interventions in this population can
preserve pancreatic beta cells, and improve their* Correspondence: foadoddini@bums.ac.ir
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article, unless otherwise stated.performance [3]. Current medications to control blood
glucose and lipid profile may have dangerous side effects
over time such as increased risk of weight gain, liver tox-
icity, and cardiovascular diseases [4]. Thus, we need to
use stronger alternatives with less side effects. In this line,
nutritional interventions, change in lifestyle, and behav-
ioral therapy are on the rise. However, these interven-
tions may not be effective alone to prevent the
development of type 2 diabetes [5].
Aloe (Aloe vera L., Liliaceae family) has applications in
health and cosmetic products as well as antioxidant, an-
ticancer, anti-inflammatory, laxative, anti-atherosclerosis
properties. It includes 75 active components that
contain vitamins, enzymes, minerals, sugars, Lignin, sali-
cylic acid, and amino acids [6,7]. Plenty of major compo-
nents such as: Aloe-emodin, Aloetic-acid, Anthranol,
Barbaloin, Mannan and its derivatives, 8-C-glusoly-(2′-O-
cinnamoly), −7-O-methlyaloediol A, Alkaline phosphatese,Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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dase, cyclooxygenase, lipase, oxidase, phosphoenol-
pyruvate, carboxylase, superoxide dismutase, Calsium,
Chlorine, Chromium, Copper, Iron, Magnesium, Ara-
chidonic acid, Y-linolenic acid, steroids, Mannose,
glucose, L-rhamnose, Aldopentose, Vitamin A, B12,
C, E, choline and folic acid, Auxins and Gibberellins
have been found [8].
In one study, the use of oral administration of Aloe
vera leaf gel extract for 21 days improved glycoprotein
metabolism in diabetic animal models [9]. There is also
evidence which shows that the glucose metabolism can
be regulated with Aloe vera. The plant has other proper-
ties such as the reduction of hepatic tissue damage
resulting from diabetic complications in rats [10] and re-
duction of the oxidative damage in the hippocampus
and cerebral cortex of mice with type 2 diabetes [11].
Although hypoglycemic properties of Aloe vera have
been reported for years [12], few human studies have been
carried out so far [7,13-15]. Most of these studies have
been implemented on patients with diabetes while some of
such studies suffered from methodological weaknesses.
Individuals at risk for type 2 diabetes are increasing.
On the one hand, simple and available remedies are re-
quired; on the other hand, no side effects for Aloe vera
gel extract have been reported [14,15]. Thus, the present
study was conducted to investigate the effects of two dif-
ferent doses of Aloe vera extract, and to determine the
least time needed, to improve glucose and lipid profile
levels in pre-diabetes subjects.
Materials and methods
This study was a double blind randomized controlled
trial done in the Research Center of Birjand University
of Medical Sciences (BUMS) in November 2013. It was
approved by the Methodology and Ethics Committee of
BUMS on May, 2, 2013 with the 92.02.03 code number.
Further, the trial was registered in the Iranian Registry of
Clinical Trials with the number IRCT2013041112984N1.
This study was done on 72 volunteers who were se-
lected according to entry criteria including an age be-
tween 35 to 65 years; fasting blood glucose between 100
and 125 mg/dl; HbA1C between 5.7 to 6.4; TG between
200–150 mg/dl; CHOL-C between 250–200 mg/dl;
HDL-C less than 35 mg/dl; LDL-C between 130–160
mg/dl; BMI between 25–30; no use of any lipid-lowering
treatment and no has any serious stress during last two
months. The exclusion criteria involved a serious stress
in the last 8 weeks; a history of type 2 diabetes or gesta-
tional diabetes; pregnancy; breastfeeding; allergy to Aloe
vera or products containing it before or during the
study; dissatisfaction to continue the study; liver and
kidney disease; chronic respiratory problems or thyroid
problems or infections that are inexcusable; electivesurgery in the last two months; and absence from study
for more than one week.
At first, the methodology was explained to volunteers
as clearly and simply as possible and then obtained their
informed consent. We used a formula comparing differ-
ence between two means for independent groups (power
calculation = 80%) based on Devaraj et al. [14] study re-
sults. According to purposive non-probability sampling,
blocking randomization method was used for the ran-
dom allocation of patients among three groups (n = 24):
Aloe vera groups (AL300, AL500) and placebo group
(PL). The AL300 and AL500 groups received two cap-
sules per day which contained 300 and 500 mg pure
powdered of Aloe vera extract (Barij Essence Company,
Kashan, Iran). The PL group received capsules that con-
tained micro-crystalline cellulose (Aldrich, America). All
the participants took the capsules after breakfast and
after dinner for as long as eight weeks.
At the beginning of the study, fasting blood sample
was taken to check for glucose and lipid profiles through
standard methods. Plasma variables were measured by
chemistry analyzer (Prestige 24i, Japan) using biochem-
ical kits (ParsAzmoon, Iran) in one laboratory. Their
BMI was calculated (based on measured their height by
Seca 206, Germany and their weight by Beurer-PS07,
Germany) and their systolic and diastolic blood pres-
sures (standard sphygmomanometer) were also mea-
sured by one nurse. Then, the package of capsules with
the timeline of how to use them was given to the partici-
pants. Participants visited the Research Center to give
blood sample at the end of the fourth and eighth weeks
of the study. The researcher’s phone number was given
to the participants for probable queries. In addition, all
the participants were reminded to take the pills and
were emphasized not to use any other herbal medicine
through phone calls.
Finally, they were requested not to have any change in
their diet and routine activities during the study.
Statistical analysis
All results are presented as mean ± SD. Statistical ana-
lysis was done in SPSS (version 16, SPSS Inc, Chicaogo,
IL) using one-way ANOVA followed by Tukey’s or
Bonferroni tests for parametric variables. For non-
parametric variables (HbA1C, CHOL-C, HDL-C),
Friedman and Wilcoxon tests were used to analyze
within-group changes, and Kruskal-Wallis and Mann–
Whitney tests were used to assess changes between groups.
Chi-square test was used for comparing sex status. Signifi-
cance level was considered at p < 0.05.
Results
It is a double blind randomized controlled trial that was
done on 72 pre–diabetes volunteers. The mean age of
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of them were women. Demographic characteristics and
studied parameters for the subjects in different groups
are presented in Table 1.
The sample of the study included 72 volunteers. How-
ever, towards the end of the intervention, one participant
from 300 mg capsule of Aloe vera left the study for un-
willingness to continue the study, and one person from
the placebo group had to leave for an emergency appen-
dicitis operation. Finally, the sample involved 70 people
(see Figure 1).
Chi-square and ANOVA test indicated homogeneity of
demographic variables in different groups. Blood pres-
sure of participants was not high at baseline, nor at the
end of the intervention (Data not shown). No adverse ef-
fects were reported during the use of Aloe vera extract.
Capsules were well tolerated and no complaint was re-
ceived about the taste or smell of them. Usage of Aloe
vera extract during the 8-weeks had the following
results:
Fasting blood glucose levels in AL300 and AL500
groups decreased significantly four weeks (respectively:
p = 0.006 and p = 0.001) and eight weeks (respectively
p = 0.002, p < 0.001) after the intervention compared
with those of the control group during the same time
span. In fact, fasting blood glucose levels had no change in
the control group during the study. Also, HbA1C level in
both case groups had a significant decrease in the eighth
week of the study (respectively, p = 0.042 and p = 0.011),




Age (years) 54.5 ± 7.7
Man (6) 26.1%
Woman (17) 73.9%
BMI (kg/m2 ) 27.9 ± 1.2
Height (cm) 159.7 ± 4.5
Weight (kg) 71.4 ± 4.4
HbA1C 6 ± 0.16
CHOL-C (mg/dl) 242.7 ± 3.13
HDL-C (mg/dl) 31.9 ± 1.2
LDL-C (mg/dl) 149.7 ± 5.2
Triglyceride (mg/dl) 173 ± 6.7
FBS (mg/dl) 110.1 ± 3.9
Systolic blood pressure (mmHg) 127.8 ± 3.3
Diastolic blood pressure (mmHg) 53.4 ± 5.5
*Chi-square test was used to check the homogeneity of gender in the three groups
variables at baseline.Only in AL500 group, the amount of CHOL-C and
LDL-C had a significant decrease in the eighth week
(respectively, p < 0.001 and p = 0.01) while their HDL-C
levels in the group increased (p = 0.004) at the end of
the study. Furthermore, the results of this study indicate
that consumption of four to eight weeks of the 500-mg
capsules of Aloe vera can significantly reduce the levels
of triglycerides of plasma (respectively p = 0.045 and
p = 0.005) compared with baseline.
To compare the effects of different doses of Aloe vera
between the groups, the mean changes of each parameter
during similar time periods were calculated and analyzed.
Levels of FBS and HbA1C in case groups had a significant
decrease compared with corresponding periods in the con-
trol group. Levels of CHOL-C, LDL-C, and TG in just
eight weeks after receiving 500 mg capsules of Aloe vera
extract showed a significant decrease compared with the
same values of the control group. However, regarding
HDL-C level, both 300 and 500 mg doses of Aloe vera ex-
tract significantly reduced compared with the control
group (p < 0.05) at the eighth week of the study.
Discussion
Pre-diabetes is a serious global epidemic that increases
the risk of getting type 2 diabetes by fivefold and the
probability of cardiovascular disease by two times. A pri-
mary preventive measure for this disease is lifestyle
modification, which is usually difficult. Therefore, it is
necessary to utilize other therapies to reduce the conse-






49.5 ± 7.5 53.2 ± 9.9 0.14
(5) 21.7% (10) 41.7% 0.29*
(18) 78.3% (14) 58.3%
28.6 ± 1 28.2 ± 1.1 0.14
159.2 ± 7.5 161 ± 7.5 0.6
72.2 ± 7.4 74.4 ± 7.2 0.3
6 ± 0.24 6 ± 0.23 0.37
241.4 ± 6.9 234 ± 1 0.14
30.4 ± 1.5 31.1 ± 2 0.74
148.7 ± 4.5 156.1 ± 5.1 0.12
176.4 ± 7.5 179.7 ± 1.1 0.07
112.2 ± 2.5 111 ± 4.1 0.149
125.8 ± 4.1 126.2 ± 4.7 0.23
50.2 ± 4.6 51.8 ± 5 0.10
; one-way analysis of variance was used to examine the homogeneity in other
Figure 1 Flowchart of the design, groups, and the participants in the project.
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Aloe vera extract at different time spans were studied on
blood glucose and lipids in diabetic patients. The results
of this study showed that both the 300 and 500 mg Aloe
vera capsules within one and two months significantly
reduced fasting blood glucose levels. Also, the capsules
significantly decreased hemoglobin by the end of the
study. Similar studies indicate that Aloe vera extract is
effective in increasing insulin sensitivity, reducing fasting
blood glucose, and decreasing the level of HbA1C in pa-
tients with pre-diabetes during eight weeks [14]. Severalhuman studies have reported the anti-diabetic effects of
Aloe vera extract [13,15]. In models of type I diabetes la-
boratory animals, it is shown that Aloe vera extract had
a similar effect on blood glucose to that of glibenclamide
[18]. Even in patients who did not respond to glibencla-
mide alone, consumption of Aloe vera extract for 2
weeks could reduce fast blood glucose [13]. Other stud-
ies have also shown the effectiveness of Aloe vera extract
on the regulation of blood glucose levels in diabetic ani-
mals [9,19]. Few studies have indicated a rise in blood
sugar levels after consumption of Aloe vera extract [20]
Table 2 Comparison of the level of glucose and lipid profiles in Aloe vera- and placebo-treated groups
Variables Time PL Within group AL300 Within group AL500 Within group Between group
N = 23 P-value N = 23 P-value N = 24 P-value P-value
FBS (mg/dl) Before intervention 110 ± 3.91 - 112 ± 2.5 - 111 ± 4.1 - 0.69
Fourth week 109 ± 4.14 0.92 109 ± 2.77* 0.006 108 ± 3.9* 0.001 0.009*
Eighth week 110 ± 4.22 0.19 108 ± 2.78* 0.001 104 ± 4.2* <0.001 0.001*
Hb A1C (%) Before intervention 6.01 ± 0.16 - 6 ± 0.24 - 6 ± 0.23 - 0.37
Eighth week 6.03 ± 0.14 0.059 5.8 ± 0.21* 0.042 5.6 ± 0.33* 0.011 0.04*
LDL-C (mg/dl) Before intervention 149.7 ± 1.08 - 148.7 ± 0.94 - 151.6 ± 1.04 - 0.12
Fourth week 150 ± 1.13 0.29 147.5 ± 0.52 0.24 146 ± 1.32 0.12 0.06
Eighth week 150.7 ± 1.2 0.34 145.4 ± 1.31 0.37 137.5 ± 1.44* 0.01 0.01*
CHOL-C (mg/dl) Before intervention 242 ± 3.13 - 241 ± 6.9 - 243 ± 10.4 - 0.21
Fourth week 242 ± 3.24 0.73 238 ± 6.4 0.25 228 ± 11.6 0.053 0.04*
Eighth week 243 ± 3.52 0.92 235 ± 8.1 0.13 218 ± 11.81* <0.001 0.006*
TG (mg/dl) Before intervention 173 ± 1.41 - 176.4 ± 1.5 - 179 ± 2.26 - 0.78
Fourth week 173.3 ± 1.41 0.54 178.2 ± 2 0.19 174.8 ± 2.35 0.045 0.1
Eighth week 173.6 ± 1.41 0.82 175.4 ± 2.08 0.072 168.6 ± 2.87* 0.005 0.03*
HDL-C (mg/dl) Before intervention 31.95 ± 1.29 - 30.43 ± 1.50 - 31.1 ± 2.05 - 0.26
Fourth week 31.82 ± 1.15 0.18 33.6 ± 3.99 0.25 33.6 ± 3.99 0.11 0.01*
Eighth week 31.69 ± 1.45 0.09 35.3 ± 3.73* 0.08 35.3 ± 3.73* 0.004 0.007*
The within groups p values are for the comparison between the fourth week or the eighth week with baseline in the same group. * p <0.05: compared with the
corresponding time in the placebo group.
All data are expressed as Mean ± SD. PL = placebo group. AL300 = the group that received 300 mg capsule of Aloe vera. AL500 = the group that received 500 mg
capsule of Aloe vera.
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the plant (not the gel) or short duration of the interven-
tion (2 times a day for 3 days).
Researchers have also introduced an important elem-
ent in the hypoglycaemic effects of Aloe vera in a sub-
stance called Acemannan. This is actually a D-isomer of
compound polysaccharide that is extracted from Aloe
vera leaf gel and has such properties as anti-virus, anti-
cancer, digestive, and immune stimulating properties
[14]. Aloe vera also contains other compounds such as
hydrophilic fiber, glucomannan [21], and phytosterol
[22] that reduce blood glucose.
It is suggested that Aloe vera can increase insulin sen-
sitivity in the cells with reduce the level of blood glucose
and insulin in serum [19] perhaps the Aloe vera can
increase the Insulin Genetics activity In pancreatic
beta cells. Study on the effects of anti-diabetic extract
of Aloe vera showed that this plant cannot reduce the
level of blood glucose in non-diabetic animals which is
contrary to the results for hypoglycemic effects of gly-
benclamid [23].
The results of this study showed that AL500 could sig-
nificantly reduce the levels of total cholesterol, TG, and
LDL-C, and increase the level of HDL-C significantly
during the 60 days of drug intake. However, AL300
could only increase the level of HDL-C in 60 days thanbefore. For the first time, Agrawal studied the effect of
Aloe vera on 5000 patients with type 2 diabetes for
5 years. After this period, a significant reduction was
shown in the level of total cholesterol and triglycerides
[12] that is consistent with our data. In another study,
Aloe vera extract in dose of 300 mg was given on a daily
basis to patients with type 2 diabetes for two months.
The results indicated a significant reduction in the level
of total cholesterol and LDL-C that are similar to our re-
sults. However, Aloe vera did not affect the level of
HDL-C and triglycerides [15]. The reason may lie with
the fact that only the 300-mg capsules of Aloe vera were
used in that study on a population of type 2 diabetic
patients who had high levels of blood glucose where, we
know, that high levels of blood glucose can cause com-
plex problems such as stress oxidative that will lead to
the development of type 2 diabetes [24].
Also, it has been demonstrated that acute and chronic
increase in the levels of blood glucose could increase the
level of serum lipids (cholesterol, triglycerides, LDL,
VLDL and decreased levels of HDL) [25]. The researcher
believes that the reason for lack of response to this dose
of Aloe vera (300 mg) capsules in this study was high
chronic level of blood glucose in patients or the low
dose of Aloe vera. It is conjectured that Aloe vera can
bring the distribution of fatty acids in the blood to
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the liver. In fact, Aloe vera extract can construct non-
saturated fatty acids that remove free radicals from
blood stream and control the metabolism of lipids in the
body [18].
It is known that beta Sistostrol, Camposterol, and Stig-
mosterol are of close similarity to Phytosterols. Besides,
it is found that beta Sistostrols chain available in some
plants such as Aloe vera can significantly decrease the
level of plasma total cholesterol, LDL-C, and triglycer-
ides by inhibiting activation of fat absorption mecha-
nisms [26]. In one study, it was shown that the use of
Aloe vera extract as much as 200 mg/kg on a daily basis
for as long as 100 days can significantly reduce the level
of cholesterol, Triglycerid, free fatty acids, and phospho-
lipids in normal mice [27]. It is also shown that taking
Aloe vera extract for 8 weeks in diabetic rats can lower
the level of cholesterol and TG [19]. Nonetheless, Aloe
vera is beneficial even in short-term intakes (21 days) of
300 mg dose [24]. Some studies have mentioned that
maximal dose of 50 mg Aloe vera could not improve the
level of cholesterol in diabetic rats [22]. This suggests
that the dose of Aloe vera that is required to reduce the
level of cholesterol of serum is higher than the dose
needed for reducing the level of blood glucose.
In a clinical trial conducted on 36 patients with type 2
diabetes, it was found that Aloe vera could reduce the
level of triglycerides but had no effects on the level of
cholesterol after daily use of one tablespoon of Aloe vera
along with glibenclamide for 6 weeks [13] which are not
similar to the results of our study. Perhaps, high blood
glucose which may in turn lead to increased levels of
blood lipid in the patients may suggest that they were
taking lipid-lowering drugs instead of complementary
medicine. The patient took Aloe vera juice which was
not of sufficient accuracy to determine the exact amount
of medication received. Devaraj and colleagues also
showed, that taking two 500 mg capsules of Aloe vera
(AC952) on a daily basis was effective in lowering the
level of LDL and total cholesterol, is consistent with the
results of our study. However it was not found to be ef-
fective in reducing the level of triglyceride and increas-
ing the level of HDL-C of the serum [14]. Perhaps, it
was because of the small number of participants in each
group (n =15) or the little amount of active ingredients
in the gel of, which can be as a result of the specific
method of pasteurization and separation of the extract.
It was also reported that a high intake of Aloe vera
(2 tablespoons three times daily for 12 weeks) could
reduce the level of triglyceride of serum without ef-
fect on the levels of cholesterol, while no renal or
hepatic toxicity was observed [7]. Increased activity
of hormone-sensitive lipase during insulin secretion
defect, increased release of free fatty acids from fat tissue.Thus, it produces more phospholipids and cholesterol in
the liver due to accumulation of fatty acids in plasma.
These two substances are released into the bloodstream as
triglycerides which can increase the level of lipoproteins in
the blood. It is suggested that can reduce the level of lipids
in blood by controlling the fat metabolism in the liver
[28]. Another theory is that the Aloe vera extract can
lower the level of blood glucose and lipid in diabetic rats
by improving sensitivity of cells to insulin [19,29]. It is well
known that Aloe vera extract can suppress the adipogene-
sis gene and suggested that the plant can improve insulin
resistance by reducing toxic effects of fat in the liver [19].
We had some limitations in quantitative control of
some confounder variables such as food intake which
could be considered for future researches.
Conclusion
Use of Aloe vera extract in pre–diabetic patients can sig-
nificantly regulate levels of fast blood glucose within four
weeks and revert the levels of lipid profile, within eight
weeks. It could be an interesting supplement strategy to
alleviate impaired serum glucose level and lipid profile.
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